Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

كتاب للدكتور وليد عمار حول النظام الصحي والإصلاح في لبنان-2003


Health spending in Lebanon is growing rapidly and faster than GDP. The current financing and delivery arrangements, extensively described in this book, are responsible for the resulting poor value for money. Reform is needed to adapt the health system with financial constraints and changing demographic and epidemiological profiles, and to produce the desired health outcomes. Lebanon's experience in introducing reform measures within a pluralistic health system, is interesting for many EMR countries, which consider enhancing the private sector role in health care provision and financing. This book provides evidence that, in the absence of proper regulation, the public financing of private services feed the escalation of health expenditures, while private insurance takes full advantage of the weak regulation capability of the public administration. It provides an analysis of the health care market and assesses the impact of the supply and different payment mechanisms on the demand and the cost of medical services.

This book does not only target experts and health professionals but is also a useful reference for students in medical and public health schools. It exposes them to different approaches for evaluating a health system, comparing utilization rates and incurred expenses between financing agencies, and calculating national health accounts. Finally, it introduces different reform components, proposes their gradual integration and gives the global picture of change for the future. 

Contents:

Chapters:
 I-    The Challenging Context
 II-   Provision of Health Services
 III-  Financing of The Health System
 IV-   Characteristics of The Market
 V-    Evaluation of The Health System
 VI-   Health Sector Reform
 VII-  Health Financing Reform and Stakeholder Analysis
 
 
    1
    ...
ATC Name B/G ↑ Ingredients Dosage Form Price
N06AX26 BRINTELLIX B Vortioxetine - 5mg 5mg Tablet, film coated 2,592,272 L.L
N06AX26 BRINTELLIX B Vortioxetine - 10mg 10mg Tablet, film coated 4,345,987 L.L
N06AX26 BRINTELLIX B Vortioxetine - 20mg 20mg Tablet, film coated 6,927,508 L.L
R03AL11 BREZTRI AEROSPHERE B Formoterol fumarate dihydrate - 5mcg, Glycopyrronium Bromide - 7.2mcg, Budesonide - 160mcg Inhalation suspension 6,705,774 L.L
A07BA01 BIOCARBON B Activated charcoal - 250mg 250mg Tablet 1,158,392 L.L
D07AC01 BETNOVATE B Betamethasone - 0.1% 0.1% Solution 235,172 L.L
D07AC01 BETNOVATE B Betamethasone (valerate) - 0.1% 0.1% w/w Cream 279,519 L.L
D07AC01 BETNOVATE B Betamethasone (valerate) - 0.1% 0.1% w/w Ointment 279,519 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated L.L
A07EA06 BUDENOFALK B Budesonide - 3mg 3mg Capsule 8,554,692 L.L
C09BA04 BI-PRETERAX ARGININE B Perindopril arginine - 5mg, Indapamide - 1.25mg Tablet, film coated 452,875 L.L
J01EE01 BACTRIM FORTE B Trimethoprim - 160mg, Sulfamethoxazole - 800mg Tablet 344,024 L.L
C09BA04 BI-PRETERAX ARGININE B Perindopril arginine - 10mg, Indapamide - 2.5mg Tablet, film coated 765,990 L.L
G04BD12 BETMIGA B Mirabegron - 50mg 50mg Tablet, prolonged release 3,758,727 L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution 2,109,833 L.L
J05AR20 BIKTARVY B Bictegravir - 50mg, Emtricitabine - 200mg, Tenofovir alafenamide - 25mg Tablet, film coated 76,569,138 L.L
C03CA02 BURINEX B Bumetanide - 1mg 1mg Tablet 335,961 L.L
C03CA02 BURINEX B Bumetanide - 5mg 5mg Tablet 1,054,916 L.L
M05BA04 BINOSTO B Alendronate sodium - 70mg 70mg Tablet, effervescent 1,709,368 L.L
M05BA06 BONVIVA B Ibandronic acid - 150mg 150mg Tablet, film coated 1,265,900 L.L
M05BA06 BONDRONAT B Ibandronic acid (monosodium monohydrate) - 6mg/6ml 6mg/6ml Injectable concentrated powder for solution 24,963,868 L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated L.L
N07BC01 BUVIDAL B Buprenorphine - 8mg 8mg Injectable solution prolonged release 8,524,771 L.L
N07BC01 BUVIDAL B Buprenorphine - 16mg 16mg Injectable solution prolonged release 8,524,771 L.L
N07BC01 BUVIDAL B Buprenorphine - 24mg 24mg Injectable solution prolonged release 8,524,771 L.L
N07BC01 BUVIDAL B Buprenorphine - 32mg 32mg Injectable solution prolonged release 8,524,771 L.L
N07BC01 BUVIDAL B Buprenorphine - 64mg 64mg Injectable solution prolonged release 34,835,645 L.L
N07BC01 BUVIDAL B Buprenorphine - 96mg 96mg Injectable solution prolonged release 34,835,645 L.L
N07BC01 BUVIDAL B Buprenorphine - 128mg 128mg Injectable solution prolonged release 34,835,645 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026